TY - CHAP A1 - Lucia Messingerova A2 - Denisa Imrichova A3 - Martina Coculova A4 - Marian Zelina A5 - Lucia Pavlikova A6 - Helena Kavcova A7 - Mario Seres A8 - Viera Bohacova A9 - Boris Lakatos A10 - Zdena Sulova A11 - Albert Breier ED1 - Ota Fuchs Y1 - 2016-09-07 PY - 2016 T1 - Different Mechanisms of Drug Resistance in Myelodysplastic Syndromes and Acute Myeloid Leukemia N2 - This book is a comprehensive overview of myelodysplastic syndromes (MDS). MDS are a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, peripheral cytopenias, frequent karyotypic abnormalities, and risk of transformation to acute myeloid leukemia (AML). Median age of patients with MDS is about 70 years. Various immune abnormalities occur in MDS patients, and the relationship between autoimmune disorders and MDS is described. Accurate prognostication and risk stratification for individual patients with MDS are important for clinical treatment decisions. Patients with MDS are classified into two broad prognostic categories: lower risk and higher risk. The approval of lenalidomide, azacitidine, and decitabine in last 10 years helped to diminish the clinical impact of MDS and delayed its progression to AML. BT - Myelodysplastic Syndromes SP - Ch. 7 UR - https://doi.org/10.5772/63483 DO - 10.5772/63483 SN - 978-953-51-2587-7 PB - IntechOpen CY - Rijeka Y2 - 2022-05-25 ER -